SARS-CoV-2 spike protein diversity at an intra-host level, among SARS-CoV-2 infected individuals in South Africa, 2020 to 2022.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 08 12 2022
accepted: 15 05 2023
medline: 1 6 2023
pubmed: 30 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Intra-host diversity studies are used to characterise the mutational heterogeneity of SARS-CoV-2 infections in order to understand the impact of virus-host adaptations. This study investigated the frequency and diversity of the spike (S) protein mutations within SARS-CoV-2 infected South African individuals. The study included SARS-CoV-2 respiratory samples, from individuals of all ages, received at the National Health Laboratory Service at Charlotte Maxeke Johannesburg Academic hospital, Gauteng, South Africa, from June 2020 to May 2022. Single nucleotide polymorphism (SNP) assays and whole genome sequencing were performed on a random selection of SARS-CoV-2 positive samples. The allele frequency (AF) was determined using TaqMan Genotyper software for SNP PCR analysis and galaxy.eu for analysis of FASTQ reads from sequencing. The SNP assays identified 5.3% (50/948) of Delta cases with heterogeneity at delY144 (4%; 2/50), E484Q (6%; 3/50), N501Y (2%; 1/50) and P681H (88%; 44/50), however only heterogeneity for E484Q and delY144 were confirmed by sequencing. From sequencing we identified 9% (210/2381) of cases with Beta, Delta, Omicron BA.1, BA.2.15, and BA.4 lineages that had heterogeneity in the S protein. Heterogeneity was primarily identified at positions 19 (1.4%) with T19IR (AF 0.2-0.7), 371 (92.3%) with S371FP (AF 0.1-1.0), and 484 (1.9%) with E484AK (0.2-0.7), E484AQ (AF 0.4-0.5) and E484KQ (AF 0.1-0.4). Mutations at heterozygous amino acid positions 19, 371 and 484 are known antibody escape mutations, however the impact of the combination of multiple substitutions identified at the same position is unknown. Therefore, we hypothesise that intra-host SARS-CoV-2 quasispecies with heterogeneity in the S protein facilitate competitive advantage of variants that can completely/partially evade host's natural and vaccine-induced immune responses.

Identifiants

pubmed: 37253027
doi: 10.1371/journal.pone.0286373
pii: PONE-D-22-33658
pmc: PMC10228762
doi:

Substances chimiques

spike protein, SARS-CoV-2 0
Spike Glycoprotein, Coronavirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0286373

Informations de copyright

Copyright: © 2023 Subramoney et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Cell Discov. 2020 Oct 29;6(1):76
pubmed: 33298872
Nature. 2021 Jul;595(7865):17-18
pubmed: 34158664
Cell Discov. 2022 Jul 25;8(1):70
pubmed: 35879274
J Clin Microbiol. 2022 Apr 20;60(4):e0240821
pubmed: 35369709
Infection. 2022 Apr;50(2):309-325
pubmed: 34914036
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Infect Drug Resist. 2021 Oct 27;14:4471-4479
pubmed: 34737587
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
Int J Infect Dis. 2022 Jan;114:178-182
pubmed: 34757008
Nat Commun. 2021 Sep 22;12(1):5469
pubmed: 34552091
Viruses. 2021 Jan 19;13(1):
pubmed: 33477885
Cell Rep. 2022 Jan 11;38(2):110205
pubmed: 34982968
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
bioRxiv. 2022 Mar 02;:
pubmed: 35262083
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Geroscience. 2022 Oct;44(5):2337-2345
pubmed: 35739343
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
J Med Virol. 2022 Aug;94(8):3676-3684
pubmed: 35441368
Clin Infect Dis. 2022 Aug 24;75(1):e144-e156
pubmed: 35134129
Virus Evol. 2021 Apr 21;7(1):veab041
pubmed: 34035952
Genome Med. 2021 Feb 22;13(1):30
pubmed: 33618765
Virulence. 2021 Dec;12(1):1209-1226
pubmed: 34030593
BMC Infect Dis. 2021 Dec 27;21(1):1282
pubmed: 34961470
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Gene. 2022 Mar 1;813:146113
pubmed: 34896524
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Med Virol. 2022 May;94(5):1808-1810
pubmed: 35043399
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
Nat Commun. 2022 May 24;13(1):2891
pubmed: 35610270
Vaccines (Basel). 2021 Aug 20;9(8):
pubmed: 34452053
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Virus Evol. 2021 Sep 29;7(2):veab078
pubmed: 34642605

Auteurs

Kathleen Subramoney (K)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Nkhensani Mtileni (N)

Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Ashlyn Davis (A)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Jennifer Giandhari (J)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Houriiyah Tegally (H)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.

Eduan Wilkinson (E)

Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.

Yeshnee Naidoo (Y)

Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.

Yajna Ramphal (Y)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Sureshnee Pillay (S)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Upasana Ramphal (U)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Andiswa Simane (A)

Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Bhaveshan Reddy (B)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Bonolo Mashishi (B)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Nonhlanhla Mbenenge (N)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Tulio de Oliveira (T)

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.

Burtram C Fielding (BC)

Molecular Biology and Virology Research Laboratory, Department of Medical BioSciences, University of the Western Cape, Cape Town, South Africa.

Florette K Treurnicht (FK)

School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Virology, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH